Aptinyx Announces Pricing of Public Offering of Common Stock
October 21 2020 - 10:59PM
Business Wire
Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical
company developing transformative therapies for the treatment of
brain and nervous system disorders, today announced the pricing of
its public offering of 14,000,000 shares of its common stock at a
public offering price of $3.00 per share. All of the shares sold in
the offering will be sold by Aptinyx. In addition, Aptinyx has
granted the underwriters a 30-day option to purchase up to
2,100,000 additional shares of common stock at the public offering
price, less underwriting discounts and commissions.
The gross proceeds from the offering, before deducting
underwriting discounts and commissions and offering expenses
payable by Aptinyx, are expected to be $42.0 million, excluding any
proceeds from the exercise of the underwriters’ option to purchase
additional shares. The proposed offering is expected to close on
October 26, 2020, subject to customary closing conditions.
SVB Leerink, Piper Sandler and Cantor are acting as joint
bookrunning managers for the offering. Wedbush PacGrow is acting as
passive bookrunning manager and H.C. Wainwright & Co. is acting
as lead manager for the offering.
Aptinyx intends to use the net proceeds received from the
offering to advance the development of its novel NMDA receptor
modulators, including NYX-2925, NYX-783, and NYX-458, in
development for chronic pain, PTSD, and cognitive impairment,
respectively, and for working capital and other general corporate
purposes.
The shares of common stock in the public offering will be issued
by Aptinyx pursuant to a shelf registration statement that was
previously filed with, and declared effective by, the Securities
and Exchange Commission (the “SEC”). The offering will be made only
by means of the written prospectus and prospectus supplement that
form a part of the registration statement. A final prospectus
supplement and the accompanying prospectus relating to the public
offering will be filed by the Company with the SEC. Copies of the
final prospectus supplement and the accompanying prospectus may be
obtained, when available, on the SEC's website at
http://www.sec.gov or by contacting SVB Leerink LLC, Attention:
Syndicate Department, One Federal St., 37th Floor, Boston, MA,
02110, by telephone at (800) 808-7525, ext. 6132, or by email at
syndicate@svbleerink.com; or Piper Sandler & Co., Attn:
Prospectus Department, 800 Nicollet Mall, J12S03, Minneapolis, MN,
55402, by telephone at (800) 747-3924, or by email at
prospectus@psc.com; or Cantor Fitzgerald & Co., Attention:
Capital Markets, 499 Park Ave., 6th Floor, New York, NY, 10022, or
by email at prospectus@cantor.com.
This press release shall not constitute an offer to sell or a
solicitation of an offer to buy these securities, nor shall there
be any offer or sale of these securities in any state or
jurisdiction in which such offer, solicitation or sale would be
unlawful prior to the registration or qualification under the
securities laws of any such state or jurisdiction.
About Aptinyx
Aptinyx Inc. is a clinical-stage biopharmaceutical company
focused on the discovery, development, and commercialization of
proprietary synthetic small molecules for the treatment of brain
and nervous system disorders.
Forward-Looking Statements
Statements contained in this press release regarding matters
that are not historical facts are “forward-looking statements”
within the meaning of the Private Securities Litigation Reform Act
of 1995. Because such statements are subject to risks and
uncertainties, actual results may differ materially from those
expressed or implied by such forward-looking statements. Such
statements include, but are not limited to, statements regarding
the expected gross proceeds and closing of the offering. Risks that
contribute to the uncertain nature of the forward-looking
statements include: the success, cost, and timing of the company’s
product candidate development activities and planned clinical
studies; the company’s ability to execute on its strategy; positive
results from a clinical study may not necessarily be predictive of
the results of future or ongoing clinical studies; regulatory
developments in the United States and foreign countries; the
company’s estimates regarding expenses, future revenue, and capital
requirements, and other financial results; as well as those risks
and uncertainties set forth in the company’s most recent Annual
Report on Form 10-K and subsequent filings with the United States
Securities and Exchange Commission. All forward-looking statements
contained in this press release speak only as of the date on which
they were made. Aptinyx undertakes no obligation to update such
statements to reflect events that occur or circumstances that exist
after the date on which they were made.
Source: Aptinyx Inc.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20201021006143/en/
Nick Smith Aptinyx Inc. ir@aptinyx.com 847-871-0377
Aptinyx (NASDAQ:APTX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Aptinyx (NASDAQ:APTX)
Historical Stock Chart
From Apr 2023 to Apr 2024